Industry: Biomedical Region: Germany Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A German applied research institute active in the field of translational biomedical engineering has developed a new inhaler platform, which has a breathing-triggered drug release system for (premature) newborns and can realize efficient inhalation drug delivery.
The technology also includes a related test bench to characterize the new inhaler platform.
The institute has developed a respiratory triggered drug release system, which uses a nasal plug with an integrated valve to improve the efficiency of inhaling aerosol. Abdominal wall movement during breathing is the trigger signal of drug aerosol release triggered by breathing. Compared with the non-trigger system, the system increases the aerosol transport by at least 4 times. It also allows targeted delivery of aerosol bolus at different inspiratory times for different lung regions. In addition, there is no suitable test method in the market for the performance test of inhalers for ventilated (premature) newborns. In this context, the research institute and a well-known medical device manufacturer jointly developed a suitable test bench to evaluate and characterize the new inhaler platform.
Cooperation mode:
The institute is now looking for industrial partners to cooperate under commercial agreements for technical assistance. In this context, the research institute is keen to cooperate with suitable companies in order to prepare for the proposed innovative products to enter the market. They want to get in touch with companies that can turn medical innovations in R&D projects into market-ready products. In addition, the institute also provides innovative technologies for licensing. Suitable partners can be experienced manufacturers or other small and medium-sized enterprises in the field of medical devices. In addition, they are keen to cooperate with suitable small and medium-sized enterprises and R&D institutions to carry out joint research projects to further develop the proposed innovations.
The partner should be an experienced research institution, which has been actively engaged in the research of inhaled aerosols. The technical solution realizes clear and time-variable drug administration to ventilated (premature) newborns. This is a unique technology that cannot be obtained elsewhere in the market.
This technique can significantly shorten the treatment time. It also allows simple adjustment of dose and dose rate. The related innovation test bench is also special and has not yet been listed on the market. This technology allows time-resolved dose rate measurement at the exit of the patient interface, simulating different breathing patterns of (premature) newborns. The institute applied for patents for these two innovations (inhaler and test bench) in Germany. The patent has not been granted.